Cancer vaccines: the next immunotherapy frontier
MJ Lin, J Svensson-Arvelund, GS Lubitz, A Marabelle… - Nature cancer, 2022 - nature.com
After several decades, therapeutic cancer vaccines now show signs of efficacy and potential
to help patients resistant to other standard-of-care immunotherapies, but they have yet to …
to help patients resistant to other standard-of-care immunotherapies, but they have yet to …
The landscape of T cell antigens for cancer immunotherapy
The remarkable capacity of immunotherapies to induce durable regression in some patients
with metastatic cancer relies heavily on T cell recognition of tumor-presented antigens. As …
with metastatic cancer relies heavily on T cell recognition of tumor-presented antigens. As …
Mismatch repair deficiency is not sufficient to elicit tumor immunogenicity
DNA mismatch repair deficiency (MMRd) is associated with a high tumor mutational burden
(TMB) and sensitivity to immune checkpoint blockade (ICB) therapy. Nevertheless, most …
(TMB) and sensitivity to immune checkpoint blockade (ICB) therapy. Nevertheless, most …
CD8+ T cells in the cancer-immunity cycle
CD8+ T cells are end effectors of cancer immunity. Most forms of effective cancer
immunotherapy involve CD8+ T cell effector function. Here, we review the current …
immunotherapy involve CD8+ T cell effector function. Here, we review the current …
Epigenetic regulation of T cell exhaustion
Chronic antigen stimulation during viral infections and cancer can lead to T cell exhaustion,
which is characterized by reduced effector function and proliferation, and the expression of …
which is characterized by reduced effector function and proliferation, and the expression of …
Cancer vaccines: Building a bridge over troubled waters
MLC Sellars, CJ Wu, EF Fritsch - Cell, 2022 - cell.com
Cancer vaccines aim to direct the immune system to eradicate cancer cells. Here we review
the essential immunologic concepts underpinning natural immunity and highlight the …
the essential immunologic concepts underpinning natural immunity and highlight the …
[HTML][HTML] Conventional type I dendritic cells maintain a reservoir of proliferative tumor-antigen specific TCF-1+ CD8+ T cells in tumor-draining lymph nodes
In tumors, a subset of CD8+ T cells expressing the transcription factor TCF-1 drives the
response to immune checkpoint blockade. We examined the mechanisms that maintain …
response to immune checkpoint blockade. We examined the mechanisms that maintain …
[HTML][HTML] Tissue-specific abundance of interferon-gamma drives regulatory T cells to restrain DC1-mediated priming of cytotoxic T cells against lung cancer
Local environmental factors influence CD8+ T cell priming in lymph nodes (LNs). Here, we
sought to understand how factors unique to the tumor-draining mediastinal LN (mLN) impact …
sought to understand how factors unique to the tumor-draining mediastinal LN (mLN) impact …
T cell egress via lymphatic vessels is tuned by antigen encounter and limits tumor control
Antigen-specific CD8+ T cell accumulation in tumors is a prerequisite for effective
immunotherapy, and yet the mechanisms of lymphocyte transit are not well defined. Here we …
immunotherapy, and yet the mechanisms of lymphocyte transit are not well defined. Here we …
Bispecific PD1-IL2v and anti-PD-L1 break tumor immunity resistance by enhancing stem-like tumor-reactive CD8+ T cells and reprogramming macrophages
M Tichet, S Wullschleger, A Chryplewicz, N Fournier… - Immunity, 2023 - cell.com
Immunotherapies have shown remarkable, albeit tumor-selective, therapeutic benefits in the
clinic. Most patients respond transiently at best, highlighting the importance of …
clinic. Most patients respond transiently at best, highlighting the importance of …